Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kevin Cook headshot

Bull of the Day: Quidel (QDEL)

by Kevin Cook

COVID and influenza A+B tests have launched sales and profit estimates triple-digits into 2021

Sweta Killa headshot

Inflation to Pick Up in 2021: Bet on TIPS ETFs

by Sweta Killa

The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.

Sweta Killa headshot

Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD

by Sweta Killa

While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.

Pfizer/BioNTech COVID-19 Vaccine Raises New Safety Concerns

by Zacks Equity Research

The Bell's palsy related side-effects are not alarming enough to preclude FDA from granting emergency approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine.

Sweta Killa headshot

5 Sector ETFs Still At Cheap Prices Amid Peak Market

by Sweta Killa

Though many sectors are hitting new highs amid the peak market, some funds are still down from a year-to-date look and are due to climb in the coming weeks.

Mark Vickery headshot

Markets Book Profits as Vaccine Rally Stalls; DASH Jumps 86% on IPO

by Mark Vickery

DoorDash (DASH) shares closed its first day on the New York Stock Exchange at $189 per share.

Micron Technology, RCI Hospitality, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Micron Technology, RCI Hospitality, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day

Sweta Killa headshot

Equal-Weight ETFs Leading Latest Market Rally: Here's Why

by Sweta Killa

While the rally has been broad-based, equal-weighted ETFs are outperforming their cap-weighted peers.

IPO Market Set to Thrive in December

by Zacks Equity Research

IPO Market Set to Thrive in December

Mark Vickery headshot

DoorDash IPOs at $102, Vaccine Rally Cooling

by Mark Vickery

DoorDash is pricing its Initial Public Offering at $102 per share, for a valuation of $38.7 billion.

Company News for Dec 9, 2020

by Zacks Equity Research

Companies In The News Are: SFIX,HRB,CMD,MRNA

Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag

by Zacks Equity Research

Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.

Mark Vickery headshot

Next Chapter in Covid-19 Era Underway

by Mark Vickery

Aside from sub-zero refrigeration requirements, the Pfizer-BioNTech vaccine looks to be first in line and among the highest efficacy rates possible.

Neena Mishra headshot

Should You Buy Oil & Gas ETFs Now?

by Neena Mishra

Energy ETFs rebounded strongly in November but are still down significantly for the year

Productivity Increases in Q3

by Zacks Equity Research

Productivity Increases in Q3

Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to Canada

by Zacks Equity Research

Moderna (MRNA) announces deal to supply 20 million additional doses of its COVID-19 vaccine candidate, mRNA-1273, to the Canadian Government, upon potential approval. The total tally is now 40 million doses.

Mark Vickery headshot

Markets Find Vaccine-Rally Equilibrium; AZO Mixed in Q1

by Mark Vickery

Great Britain injects its first Pfizer (PFE)-BioNTech (BNTX) vaccine patients today, marking a momentous occasion whereby the world may soon return to pre-pandemic activities.

Sweta Killa headshot

Small-Cap ETFs Face Off: IWM Vs. IJR

by Sweta Killa

Small-cap companies are closely tied to the U.S. economy and are thus poised to outperform when the economy improves.

Pfizer (PFE) Up 14% in 3 Months on COVID-19 Vaccine Progress

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is now approved for emergency use in United Kingdom and Bahrain.

Mark Vickery headshot

Markets Close Mixed; Toll Brothers (TOL) Puts Up Record Quarter

by Mark Vickery

It's the hottest home market Toll Brothers has seen in 30 years, with net signed contracts +68% -- an all-time high for any quarter in the company's history.

Sejuti Banerjea headshot

Can Restaurant Stocks Move Higher?

by Sejuti Banerjea

Restaurant companies have been done a lot of innovating this year and they should do much better next year as pandemic concerns wane.

The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide

Markets Hit Record Highs, Promise Further Growth: 5 Top Picks

by Zacks Equity Research

Promising vaccine news and hopes of further fiscal stimulus helped benchmark indexes to close at record highs, making this a prudent time to invest in names like Cabot (CBT) and Forestar (FOR)

Sweta Killa headshot

Holiday Shopping Shifts to E-Commerce: ETFs to Tap

by Sweta Killa

Given the digital shopping boom, stocks in the Internet and e-commerce retail space look poised for solid gains this holiday season.

Urmimala Biswas headshot

3 Growth Stocks to Tap the COVID-Driven Shift in MedTech

by Urmimala Biswas

To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.